Compugen Ltd. (CGEN.TA)
- Previous Close
749.50 - Open
749.50 - Bid 812.80 x --
- Ask 695.50 x --
- Day's Range
730.90 - 774.30 - 52 Week Range
208.10 - 1,175.00 - Volume
76,116 - Avg. Volume
127,543 - Market Cap (intraday)
684.011M - Beta (5Y Monthly) 2.68
- PE Ratio (TTM)
-- - EPS (TTM)
-0.79 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
cgen.comRecent News: CGEN.TA
Performance Overview: CGEN.TA
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CGEN.TA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CGEN.TA
Valuation Measures
Market Cap
683.47M
Enterprise Value
497.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.30
Price/Book (mrq)
2.77
Enterprise Value/Revenue
14.87
Enterprise Value/EBITDA
-39.75
Financial Highlights
Profitability and Income Statement
Profit Margin
-56.05%
Return on Assets (ttm)
-7.54%
Return on Equity (ttm)
-26.19%
Revenue (ttm)
33.46M
Net Income Avi to Common (ttm)
-18.75M
Diluted EPS (ttm)
-0.79
Balance Sheet and Cash Flow
Total Cash (mrq)
50.69M
Total Debt/Equity (mrq)
2.06%
Levered Free Cash Flow (ttm)
-51.05M
Research Analysis: CGEN.TA
Company Insights: CGEN.TA
CGEN.TA does not have Company Insights